Pituitary apoplexy (PA) is a rare, life-threatening endocrine emergency caused by acute hemorrhage and/or infarction of the pituitary gland, most commonly within a pre-existing pituitary adenoma (pituitary neuroendocrine tumor, PitNET). It complicates 2–12% of pituitary adenomas, especially nonfunctioning tumors, and occurs most frequently in men aged 50–60. [1-3]
1. History
- Headache: Sudden-onset, severe, retro-orbital or frontal, "thunderclap" quality, resistant to analgesics, and unlike prior headaches [4-5]
- Onset: Acute (minutes to hours) or subacute (days), depending on extent of hemorrhage, edema, and necrosis [3][6]
- Associated symptoms: Nausea, vomiting, visual disturbances (blurred vision, visual field cuts), diplopia, photophobia [2][7]
- Neurologic symptoms: Altered mental status, confusion, decreased level of consciousness [1][8]
- Endocrine symptoms: Fatigue, weakness, dizziness (secondary adrenal insufficiency); polyuria/polydipsia (rare diabetes insipidus) [4][8]
- Precipitating factors (present in up to 30%): Recent major surgery, anticoagulation, dynamic pituitary testing, hypertension, head trauma, pregnancy/postpartum, COVID-19 infection [2-3][9]
- Important negatives: Prior known pituitary adenoma, prior similar episodes, recent medication changes (dopamine agonists, anticoagulants)
2. Alarm Features
- Progressive visual loss (acuity or field deficits) — indicates optic chiasm compression [1][6]
- Altered consciousness / obtundation — suggests severe mass effect or adrenal crisis [1][3]
- Hemodynamic instability / refractory hypotension — secondary adrenal insufficiency until proven otherwise [4][8]
- Signs of meningeal irritation (neck stiffness, photophobia) — may mimic SAH or bacterial meningitis [3][10]
- Cranial nerve III, IV, or VI palsies — cavernous sinus involvement [5][11]
- Fever — can occur from chemical meningitis or hypothalamic involvement; must rule out infectious meningitis [10][12]
3. Medications
- Immediate treatment: IV hydrocortisone — 100–200 mg bolus, then 50–100 mg q6h or 2–4 mg/h continuous infusion [5][8]
- Alternative: Dexamethasone 4 mg IM q12h (may also reduce perilesional edema) [5]
- Medications that precipitate PA: Anticoagulants (warfarin, heparin, DOACs), antiplatelet agents, dopamine agonists (bromocriptine, cabergoline), GnRH agonists, estrogen therapy [3][9]
- Caution: Do NOT start levothyroxine before glucocorticoid replacement — can unmask or worsen adrenal crisis [5]
- Long-term: >50% of patients require permanent hormonal replacement (corticosteroids 60–80%, thyroid hormone 50–60%, testosterone 60–80% of men, desmopressin 10–25%) [8][13]
4. Diet
- NPO if surgical intervention is anticipated or if nausea/vomiting is severe
- Fluid and electrolyte management is critical — monitor for hyponatremia (SIADH or hypocortisolism) and hypernatremia (diabetes insipidus) [2][14]
- No specific long-term dietary triggers; standard hydration and nutrition counseling for patients on chronic glucocorticoid replacement
5. Review of Systems
- Neuro: Headache character/onset, vision changes, diplopia, mental status changes, weakness
- Ophthalmologic: Visual acuity loss, visual field deficits (bitemporal hemianopia), ptosis
- Endocrine: Fatigue, weight changes, cold intolerance (hypothyroidism), decreased libido, amenorrhea/erectile dysfunction, polyuria/polydipsia
- Cardiovascular: Hypotension, orthostasis, syncope
- GI: Nausea, vomiting, abdominal pain (adrenal crisis)
- Constitutional: Fever, malaise
6. Collateral History and Family History
- Known pituitary adenoma — most PA occurs in previously undiagnosed tumors (~80%) [5][13]
- Prior pituitary imaging or endocrine workup
- Recent surgeries, especially cardiac (CABG), or procedures involving anticoagulation [3]
- Pregnancy or postpartum status (Sheehan's syndrome as a differential) [2]
- Family history: MEN1 syndrome (multiple endocrine neoplasia type 1) — associated with pituitary adenomas
- Medication list: Anticoagulants, dopamine agonists, hormonal therapies
7. Risk Factors
- Pre-existing pituitary macroadenoma (most important risk factor) [3][9]
- Nonfunctioning adenomas > functioning adenomas [3][15]
- Hypertension (48.8% prevalence in PA patients vs 33.4% general population) [15]
- Diabetes mellitus (20.3% vs 13.9%) [15]
- Dyslipidemia (44.2% vs 23.3%) [15]
- Anticoagulant therapy or bleeding disorders [3][11]
- Major surgery (especially cardiac surgery) [3]
- Dynamic pituitary testing (insulin tolerance test, GnRH stimulation) [3]
- Head trauma, sudden changes in intracranial or arterial pressure [11]
- COVID-19 infection or vaccination (emerging association) [9]
- Radiation therapy to the pituitary region [11]
8. Differential Diagnosis
- Subarachnoid hemorrhage (SAH) — most critical mimic; thunderclap headache, meningismus; CTA/LP to differentiate [3][5]
- Bacterial meningitis — fever, neck stiffness, CSF pleocytosis; PA can cause sterile chemical meningitis with CSF pleocytosis [10]
- Ischemic stroke (especially posterior circulation) — focal deficits, imaging differentiates [5]
- Cavernous sinus thrombosis — cranial nerve palsies, proptosis, fever
- Ruptured intracranial aneurysm — MR angiography to exclude [13]
- Migraine with aura — recurrent, stereotyped, no visual field cuts on formal testing
- Craniopharyngioma with hemorrhage — imaging overlap; may show calcifications
- Rathke cleft cyst rupture — intrinsic T1 hyperintensity from proteinaceous content [16]
- Sheehan syndrome — postpartum pituitary infarction without tumor [4]
- Hypertensive emergency with headache
9. Past Medical History
- Known pituitary adenoma or incidentaloma
- Prior pituitary surgery or radiation
- History of hypertension, diabetes, dyslipidemia [15]
- Bleeding disorders or anticoagulant use
- Prior episodes of apoplexy (recurrence is possible) [1][6]
- Chronic endocrine conditions (hypothyroidism, hypogonadism, adrenal insufficiency)
- Pregnancy history (Sheehan syndrome differential)
10. Physical Exam
- Vitals: Hypotension (adrenal crisis), tachycardia, fever (up to 37.8–38.5°C from chemical meningitis or hypothalamic involvement) [12]
- Neuro-ophthalmologic (most critical exam):
- Visual acuity testing
- Visual fields to confrontation (bitemporal hemianopia from chiasmal compression)
- Pupil exam (CN III palsy → fixed dilated pupil, ptosis)
- Extraocular movements (CN III, IV, VI palsies from cavernous sinus compression) [5][11]
- Neurologic: Mental status (GCS), meningeal signs (nuchal rigidity, Kernig/Brudzinski)
- General: Signs of chronic hypopituitarism — pallor, loss of body hair, soft skin, testicular atrophy
- Cardiovascular: Orthostatic vitals
11. Lab Studies
Stat labs (draw BEFORE starting steroids if hemodynamically stable): [4][13]
- Serum cortisol and ACTH — cortisol <500 nmol/L (18 µg/dL) is subnormal in an acute setting [4]
- BMP/CMP — sodium (hyponatremia in ~42%), potassium, glucose, renal function [14]
- Free T4 and TSH
- Prolactin — often low (hypoprolactinemia <7.5 ng/mL supports PA diagnosis with 100% specificity); can also be elevated from stalk effect [12]
- LH, FSH, testosterone (men) / estradiol (women)
- IGF-1 (GH axis assessment)
Additional
- CBC — leukocytosis and elevated NLR associated with symptomatic apoplexy [14]
- Coagulation studies (PT/INR, aPTT) — especially if on anticoagulants
- Serum osmolality and urine osmolality — if diabetes insipidus suspected
- Note: Short Synacthen (cosyntropin) test can be falsely reassuring acutely because adrenal atrophy has not yet developed [4]
12. Imaging
- MRI sella with pituitary protocol — gold standard, diagnostic in >90% of cases [13][16]
- T1: High signal (methemoglobin) in subacute hemorrhage, typically peripheral
- T2: Low signal in hemorrhagic areas, high signal in cystic/necrotic areas
- Fluid-fluid level within the lesion is characteristic [5]
- Contrast: Central nonenhancement indicates necrosis/ischemia [16]
- CT head — often the first imaging obtained in the ED; diagnostic in only 21–28% but shows a sellar mass in up to 80%; useful to exclude SAH [13]
- Normal CT does NOT exclude pituitary apoplexy — MRI is essential if clinical suspicion persists [10]
- CTA or MR angiography — to exclude aneurysm if SAH is in the differential [13]
- ACR Appropriateness Criteria rate MRI sella as the primary modality for suspected PA [16]
13. Special Tests
- Pituitary Apoplexy Score (PAS) — semi-quantitative scoring system incorporating visual acuity, visual fields, and ocular palsies to guide surgical vs. conservative management; higher scores favor surgery. Limitations: does not capture persistent headache or evolving visual symptoms [1][15]
- Formal visual field testing (Humphrey or Goldmann perimetry) — should be performed within 24 hours when patient is stable [13]
- Lumbar puncture — may be performed if meningitis is suspected; CSF in PA can show pleocytosis, elevated protein, and xanthochromia (chemical meningitis), which is sterile [10]
- Serial neuro-ophthalmologic assessments — critical for detecting progression and guiding surgical timing [1][6]
14. ECG
- ECG is not a primary diagnostic tool for PA but should be obtained as part of the standard workup in acutely ill patients
- Indications: Hypotension, electrolyte abnormalities (hyponatremia, hyperkalemia from adrenal crisis), tachycardia
- Watch for QT prolongation (hyponatremia, hypocortisolism) and arrhythmias (electrolyte derangements)
- Thrombotic events have been reported in association with symptomatic PA [14]
15. Assessment
PA is a clinical syndrome, not purely a radiological finding — subclinical intratumoral hemorrhage (found incidentally in 14–25% of pituitary adenomas) does not constitute apoplexy. [3][5] The clinical spectrum ranges from isolated headache to fulminant adrenal crisis with coma. Nearly 80% of patients present with one or more anterior pituitary hormone deficiencies at diagnosis, with corticotropic deficiency being the most dangerous (>70%). [5] Diabetes insipidus is uncommon (~4% transient, ~2% permanent) due to differences in anterior vs. posterior pituitary blood supply. [8] Misdiagnosis at initial presentation is common, particularly when the underlying adenoma is unknown. [5][10]
16. Treatment Plan
Immediate stabilization (all patients)
- ABCs, IV access, continuous monitoring
- IV hydrocortisone 100–200 mg bolus → then 50–100 mg q6h (or 2–4 mg/h infusion) — start empirically even before lab confirmation if hemodynamically unstable [5][8][13]
- Draw baseline cortisol, ACTH, FT4, TSH, prolactin, LH/FSH, testosterone/estradiol, IGF-1 BEFORE steroids if patient is stable [13]
- IV fluids, correct electrolyte abnormalities (especially hyponatremia)
- Analgesics for headache, antiemetics for nausea/vomiting
Surgical decompression (transsphenoidal approach)
- Indications: Severe or progressive visual acuity/field loss, altered mental status, deteriorating neurologic status [1][6][13]
- Surgery within 7 days of symptom onset is associated with significantly better visual outcomes (OR 5.88 for recovery vs. >7 days) [17]
- ~70% of patients ultimately undergo surgery [2]
Conservative management
- Appropriate for patients with mild, stable symptoms (including isolated ocular palsies), normal consciousness, and no significant visual acuity/field deficits [3][6]
- A prospective multicenter study of 97 patients showed similar 3- and 6-month outcomes (visual, oculomotor, hormonal) between surgical and medical management [18]
- Apoplectic tumor volumes regress substantially within 2–3 months even without surgery [18]
- ~90% of conservatively managed patients show >25% spontaneous tumor shrinkage [19]
- Frequent reassessment is mandatory — clinical course can be unpredictable [6]
Hormonal management
- Taper hydrocortisone to oral maintenance doses (15–25 mg/day in divided doses) as clinically indicated [5]
- Levothyroxine if FT4 is low — only after glucocorticoid replacement is initiated [5]
- Gonadal hormone replacement deferred to outpatient setting
- 50% of patients require long-term hormonal replacement [8]
17. Disposition
- All patients with confirmed or suspected pituitary apoplexy require hospital admission [1][13]
- ICU/step-down: Hemodynamic instability, altered mental status, severe visual loss, or need for close neuro-ophthalmologic monitoring
- Neurosurgery consultation: All cases — even if conservative management is planned, surgical backup is essential [13]
- Endocrinology consultation: All cases — for hormonal assessment and replacement [13]
- Ophthalmology/neuro-ophthalmology consultation: Formal visual field testing within 24 hours [13]
- Multidisciplinary team decision (neurosurgery, endocrinology, neuro-ophthalmology) for surgical vs. conservative management [1][6][13]
18. Follow-Up / Return Precautions
- Endocrine review at 4–8 weeks post-event with full pituitary hormone panel [13]
- Annual biochemical assessment of all pituitary axes (FT4, TSH, LH, FSH, sex steroids, prolactin, IGF-1, cortisol assessment) [13]
- Formal visual field and ophthalmologic evaluation at follow-up [1]
- MRI surveillance for tumor regrowth — regrowth is possible years after the event [1][6]
- Hypopituitarism may be transient or permanent — recovery can occur weeks to months after the event; ongoing monitoring is essential [8]
- Permanent vasopressin deficiency is more common after surgery (14.8–17.9%) than conservative management (0–3.3%) [15][19]
Return precautions for patients/families
- Seek immediate care for worsening headache, new vision changes, confusion, persistent vomiting, dizziness/fainting, or signs of adrenal crisis (severe weakness, hypotension, altered consciousness)
- Patients on glucocorticoid replacement must be educated on sick-day rules and carry a medical alert identification
- Stress-dose steroids for illness, surgery, or physiologic stress
References
1. Management of Endocrine Disease: Update on the Management of Pituitary Apoplexy. — Biagetti B, Marques P, Ntali G, et al. European Journal of Endocrinology. 2026.
2. Pituitary Apoplexy: An Updated Review. — Iglesias P. Journal of Clinical Medicine. 2024.
3. Pituitary Apoplexy. — Briet C, Salenave S, Bonneville JF, Laws ER, Chanson P. Endocrine Reviews. 2015.
4. Hypopituitarism. — Higham CE, Johannsson G, Shalet SM. Lancet. 2016.
5. Multidisciplinary Management of Pituitary Apoplexy. — Albani A, Ferraù F, Angileri FF, et al. International Journal of Endocrinology. 2016.
6. Management of Endocrine Disease: Pituitary Tumour Apoplexy. — Capatina C, Inder W, Karavitaki N, Wass JA. European Journal of Endocrinology. 2015.
7. Diagnosis and Treatment of Pituitary Apoplexy, a True Endocrine Emergency. — Moscona-Nissan A, Sidauy-Adissi J, Hermoso-Mier KX, et al. Archives of Medical Research. 2024.
8. Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline. — Fleseriu M, Hashim IA, Karavitaki N, et al. The Journal of Clinical Endocrinology and Metabolism. 2016.
9. Pituitary Apoplexy: A Re-Appraisal of Risk Factors and Best Management Strategies in the COVID-19 Era. — Boyke AE, Michel M, Mamelak AN. Pituitary. 2024.
10. Pituitary Apoplexy Masquerading as Intractable Headache in a 66-Year-Old Man: A Case Report. — Heaney A, Ceraolo N, Simon EL. The Journal of Emergency Medicine. 2025.
11. Hypopituitarism. — Vance ML. The New England Journal of Medicine. 1994.
12. Differences in Clinical Course Between Pituitary Apoplexy and Non-Apoplexy Patients With Nonfunctioning Pituitary Neuroendocrine Tumors. — Taguchi A, Kinoshita Y, Tominaga A, et al. Neurosurgical Review. 2026.
13. UK guidelines for the management of pituitary apoplexy. — Rajasekaran S, Vanderpump M, Baldeweg S, et al. Clinical Endocrinology. 2011.
14. Differences in Clinical Profiles of Patients With Symptomatic and Asymptomatic Apoplexy in Pituitary Neuroendocrine Tumors. — Goyal-Honavar A, Konar S, Sadashiva N, et al. Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia. 2025.
15. Pituitary Apoplexy: Comorbidities, Management, and Outcomes-a Spanish Observational Multicenter Study. — Biagetti B, Cordero Asanza E, Pérez-López C, et al. The Journal of Clinical Endocrinology and Metabolism. 2025.
16. ACR Appropriateness Criteria Neuroendocrine Imaging. — Burns J, Policeni B, Bykowski J, et al. Journal of the American College of Radiology : JACR. 2019.
17. The Role of Intervention Timing and Treatment Modality in Visual Recovery Following Pituitary Apoplexy: A Systematic Review and Meta-Analysis. — Brown NJ, Patel S, Gendreau J, Abraham ME. Journal of Neuro-Oncology. 2024.
18. A Prospective, Multicenter, Observational Study of Surgical vs Nonsurgical Management for Pituitary Apoplexy. — Mamelak AN, Little AS, Gardner PA, et al. The Journal of Clinical Endocrinology and Metabolism. 2024.
19. Trends and Outcomes in Pituitary Apoplexy Management: A Spanish Observational Multicenter Study. — Biagetti B, Cordero Asanza E, García-Feijoo P, et al. Neurosurgery. 2024.